Leukemia, Myelodysplasia, Transplantation
Conference Coverage
Azacitidine-Gemtuzumab Combo Effective in Good-Risk AML
Major Finding: A combination of azacitidine and gemtuzumab followed by azacitidine maintenance produced a 44% complete or near-complete remission...
News
Despite efficacy, most patients discontinued therapy
In a multicenter trial, deferasirox reduced serum ferritin and labile plasma iron (LPI) in transfusion-dependent patients with myelodysplastic...
Audio
Community Oncology Podcast - Ruxolitinib for myelofibrosi
News
New Data Confirm Safety of Stopping Imatinib in Leukemia
News
New antibody achieves high CR rate in relapsed/refractory adult ALL
CHICAGO—A new monoclonal antibody, blinatumomab, achieves an “exceptionally high complete remission rate” as a single agent in acute lymphoblastic...
News
Relapsed/Refractory Leukemia Responds to Experimental Inotuzumab
Major Finding: The conjugated monoclonal antibody inotuzumab ozogamicin was associated with a 52% objective response rate in single-agent therapy...
News
Fertility Preservation No Longer Experimental for Cancer Patients
News
As CT Scans Increase, Concern of Radiation Risk Rises
Conference Coverage
Teens and Young Adults Trail Children on Pediatric Leukemia Regimens
Major Finding: The 5-year event-free survival rate reached 68% among adolescent and young adult (AYA) patients but still fell short of the 80%...